EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma	Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease	Recruiting	Phase 1 / Phase 2	2026-05-11		NCT06802835

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chongqing University Cancer Hospital	41
Dongguan People's Hospital	32
First Affiliated Hospital of Guangxi Medical University	96
Fujian Province Tumor Hospital	6
Jiangxi Provincial Cancer Hospital	33
Liuzhou Workers' Hospital	7
Second Affiliated Hospital, Zhejiang University, School of Medicine	561
Sun Yat-sen University	606
Wuhan TongJi Hospital	29
Xijing hospital of The fourth military medical university	1
Zhejiang Cancer Hospital	142

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Sun Yat-Sen University Cancer Center	Guangzhou	China	113